Basilea Pharmaceutica AG
SIX:BSLN

Watchlist Manager
Basilea Pharmaceutica AG Logo
Basilea Pharmaceutica AG
SIX:BSLN
Watchlist
Price: 55.7 CHF -0.54%
Market Cap: CHf675.1m

Net Margin

30.8%
Current
Improving
by 11.6%
vs 3-y average of 19.1%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
30.8%
=
Net Income
CHf72.7m
/
Revenue
CHf236.2m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
30.8%
=
Net Income
CHf72.7m
/
Revenue
CHf236.2m

Peer Comparison

Country Company Market Cap Net
Margin
CH
Basilea Pharmaceutica AG
SIX:BSLN
684.2m CHF
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Higher than 89% of companies in Switzerland
Percentile
89th
Based on 1 179 companies
89th percentile
30.8%
Low
-57 027.8% — 1.3%
Typical Range
1.3% — 13.7%
High
13.7% — 3 663.7%
Distribution Statistics
Switzerland
Min -57 027.8%
30th Percentile 1.3%
Median 7.2%
70th Percentile 13.7%
Max 3 663.7%

Basilea Pharmaceutica AG
Glance View

Market Cap
675.1m CHF
Industry
Biotechnology

Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. The company is headquartered in Basel, Basel-Stadt and currently employs 154 full-time employees. The company went IPO on 2004-03-25. The firm operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. The company launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.

BSLN Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
30.8%
=
Net Income
CHf72.7m
/
Revenue
CHf236.2m
What is Basilea Pharmaceutica AG's current Net Margin?

The current Net Margin for Basilea Pharmaceutica AG is 30.8%, which is above its 3-year median of 19.1%.

How has Net Margin changed over time?

Over the last 3 years, Basilea Pharmaceutica AG’s Net Margin has increased from 0.6% to 30.8%. During this period, it reached a low of -0.4% on Jun 30, 2024 and a high of 37.2% on Dec 31, 2024.

Back to Top